Skip to NavigationSkip to content

European Commission approves Genmab's Darzalex combo in newly diagnosed multiple myeloma

Published on 20/11/19 at 10:47am

Genmab’s Darzalex (daratumumab) has secured approval from the European Commission and is now authorised in Europe for the treatment of newly diagnosed multiple myeloma when used in combination with lenalidomide and dexamethasone, it has emerged.

The approval covers adult patients with condition who are ineligible for autologous stem cell transplant (ASCT), and delivers on the recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) on October, just a month prior.

Phase 3 data demonstrating the efficacy of this Darzalex combo in newly diagnosed multiple myeloma patients who are not eligible for high dose chemotherapy and ASCT was used in support of the deciusion.

Dr Jan van de Winkel, Chief Executive Officer of Genmab, commented on the ruling: “We are pleased that with this approval, patients in the European Union newly diagnosed with multiple myeloma who are not candidates for transplant will now have two potential options for treatment with Darzalex containing regimens. We look forward to seeing the combination therapy of Darzalex with lenalidomide and dexamethasone launched in Europe.”

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches